Gregory A. Maglinte

3.7k total citations · 1 hit paper
32 papers, 2.7k citations indexed

About

Gregory A. Maglinte is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gregory A. Maglinte has authored 32 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Genetics and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gregory A. Maglinte's work include Colorectal Cancer Treatments and Studies (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Gregory A. Maglinte is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Gregory A. Maglinte collaborates with scholars based in United States, United Kingdom and Switzerland. Gregory A. Maglinte's co-authors include Heinz‐Josef Lenz, Rebecca A. Moss, Jayesh Desai, Thierry André, Monica V. Goldberg, Sara Lonardi, Andrew Hill, Scott Kopetz, Michael A. Morse and Joseph L. Leach and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Gregory A. Maglinte

26 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

2017 2.0k citations Michael J. Overman, Ray McDermott et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Gregory A. Maglinte

Since Specialization

Citations

This map shows the geographic impact of Gregory A. Maglinte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Maglinte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Maglinte more than expected).

Fields of papers citing papers by Gregory A. Maglinte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Maglinte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Maglinte. The network helps show where Gregory A. Maglinte may publish in the future.

Co-authorship network of co-authors of Gregory A. Maglinte

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Maglinte. A scholar is included among the top collaborators of Gregory A. Maglinte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Maglinte. Gregory A. Maglinte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma 2025 ·Blood Advances ·Tycel Phillips, Mengyang Di, (unknown), (unknown), (unknown), Gregory A. Maglinte, Erlene Seymour, Yucai Wang	0
2	Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) 2024 ·Blood ·Jing‐Zhou Hou, (unknown), Gregory A. Maglinte, Anupama Vasudevan, (unknown), Brandon Wang, (unknown), (unknown), (unknown)	0
3	Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Lisa Y. Law, Alfredo R. Lopez, Susan Buchanan, Gregory A. Maglinte, Raymond Liu, Zheng Zhu, Lori C. Sakoda, (unknown)	0
4	Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices. 2024 ·Journal of Clinical Oncology ·Jing‐Zhou Hou, (unknown), Gregory A. Maglinte, Anupama Vasudevan, (unknown), (unknown), (unknown), (unknown), Brandon Wang, (unknown)	1
5	PCN324 Patient Reported Outcomes Among Kte-X19 CAR T Treated Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) 2020 ·Value in Health ·Marie José Kersten, (unknown), Nöel Milpied, Gregory A. Maglinte, Sarah Crawford, Caitlyn T. Solem, (unknown), M. Wang	1
6	PCN183 Global Incidence, Prevalence, and Survival in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Systematic Literature Review (SLR) 2020 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Gregory A. Maglinte	1
7	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer 2019 ·Gastric Cancer ·Ian Chau, Dung T. Le, Patrick A. Ott, Beata Korytowsky, (unknown), T. Kim Le, Ying Zhang, Teresa Sánchez, Gregory A. Maglinte, (unknown), (unknown), Dhiren Patel, (unknown)	12
8	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer 2019 ·Clinical Colorectal Cancer ·Dung T. Le, Patrick A. Ott, Beata Korytowsky, (unknown), T. Kim Le, Ying Zhang, Gregory A. Maglinte, (unknown), Dhiren Patel, (unknown), Ian Chau	22
9	Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. 2018 ·Journal of Clinical Oncology ·Yelena Y. Janjigian, Dung T. Le, Patrick A. Ott, Beata Korytowsky, (unknown), Trong Kim Le, Ying Zhang, Teresa Sánchez, Gregory A. Maglinte, (unknown), Dhiren Patel, (unknown), Ian Chau	1
10	Predicting EQ-5D Utility Index Scores for Gastric Cancer Patients in Japan: A Preliminary Model 2017 ·Value in Health ·James Pike, Gregory A. Maglinte, A. Rider, Kim Cocks, Fiona Taylor, (unknown), Emiliano Calvo	1
11	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study breakdown → 2017 ·The Lancet Oncology ·Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André	1977
12	Real-world advanced gastric cancer treatment patterns in Western and Asian countries 2017 ·Annals of Oncology ·Sun Young Rha, Emiliano Calvo, (unknown), A. Rider, Gregory A. Maglinte, Blaise Clarke, Kei Muro	1
13	Real-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Canada and Europe 2017 ·Annals of Oncology ·Gregory A. Maglinte, A. Rider, (unknown), A. Boyers, Blaise Clarke, Emiliano Calvo	1
14	Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142 2017 ·Annals of Oncology ·Michael J. Overman, Shital Kamble, Rebecca A. Moss, Fiona Taylor, Gregory A. Maglinte, James W. Shaw, Kim Cocks, (unknown), Christine Yip, Thierry André	6
15	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy 2016 ·Clinical Therapeutics ·Christopher N. Graham, Gregory A. Maglinte, Lee S. Schwartzberg, Timothy Price, (unknown), Guy Hechmati, Jonas Hjelmgren, Beth Barber, Marwan Fakih	9
16	Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-typeRASmetastatic colorectal cancer 2015 ·Journal of Medical Economics ·Christopher N. Graham, Guy Hechmati, Marwan Fakih, (unknown), Gregory A. Maglinte, Jonas Hjelmgren, Beth Barber, Lee S. Schwartzberg	7
17	The Daily Activity Report (DAR) a Novel Measure of Functional Outcome for Serious Mental Illness 2015 ·Schizophrenia Bulletin ·Dawn I. Velligan, Jim Mintz, (unknown), Mona L. Martin, (unknown), Gregory A. Maglinte, Patricia K. Corey‐Lisle	6
18	Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013 2014 ·Clinical Therapeutics ·George Coritsidis, Gregory A. Maglinte, Anjali Acharya, Anjali Saxena, Chun‐Lan Chang, Jerrold Hill, Matthew Gitlin, Richard Lafayette	5
19	The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients 2012 ·Quality of Life Research ·Regina Rendas‐Baum, Lisa Bloudek, Gregory A. Maglinte, Sepideh F. Varon	81
20	Validating Migraine‐Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine 2011 ·Headache The Journal of Head and Face Pain ·(unknown), Regina Rendas‐Baum, Gregory A. Maglinte, Min Yang, Sepideh F. Varon, Jeff Lee, Mark Kosinski	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact